Piper Jaffray Companies reiterated their buy rating on shares of Recro Pharma, Inc. (NASDAQ:REPH) in a research note published on Friday, October 27th. Piper Jaffray Companies currently has a $11.00 target price on the specialty pharmaceutical company’s stock.
Several other equities research analysts also recently issued reports on the stock. Zacks Investment Research upgraded shares of Recro Pharma from a hold rating to a buy rating and set a $8.25 price objective on the stock in a research note on Wednesday, August 16th. Roth Capital set a $20.00 price objective on shares of Recro Pharma and gave the stock a buy rating in a research note on Monday, July 31st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $12.63.
Recro Pharma (REPH) opened at $8.34 on Friday. Recro Pharma has a 52-week low of $5.81 and a 52-week high of $10.17. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59.
TRADEMARK VIOLATION WARNING: This piece was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.truebluetribune.com/2017/11/15/recro-pharmas-reph-buy-rating-reiterated-at-piper-jaffray-companies.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in Recro Pharma by 3.0% during the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock worth $150,000 after buying an additional 500 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Recro Pharma by 76.9% during the second quarter. Janney Montgomery Scott LLC now owns 22,085 shares of the specialty pharmaceutical company’s stock worth $155,000 after buying an additional 9,600 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Recro Pharma by 183.4% during the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after acquiring an additional 14,098 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Recro Pharma during the first quarter valued at $156,000. Finally, KCG Holdings Inc. bought a new position in shares of Recro Pharma during the first quarter valued at $173,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.